1 heavyweight FTSE 100 share I’d buy as London retakes its crown

Some Footsie firms are extremely large, but that doesn’t mean they couldn’t get even bigger. Here’s one such FTSE 100 share I’d buy right now.

| More on:
British flag, Big Ben, Houses of Parliament and British flag composition

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

After surging to record highs in May, FTSE 100 shares have since come off the boil a bit. But not as much as those in France, where the CAC All-Share index has fallen by around 7.4% in one month.

The index has been driven lower by uncertainty about the outcome of the nation’s looming parliamentary elections. And it means that London retook its title as Europe’s largest stock market from Paris on 17 June.

That said, a quick rebound in giant luxury stocks like Hermes International and LVMH across the Channel could quickly reverse that. It’s neck and neck.

Still, it’s encouraging to see UK blue-chip stocks getting some love recently. Valuations are attractive and dividends are high, which has been attracting overseas investors.

Here is one Footsie stock that I’d buy today, despite its enormous size.

Still growing strongly

I’m talking about AstraZeneca (LSE: AZN), which is London’s largest firm with a market cap of £192bn.

The first thing I like here is that demand for AstraZeneca’s products, which includes treatments for cardiovascular diseases and various types of cancer, is generally stable across the economic cycle.

However, the pharmaceutical giant is doing much better than stable. In 2023, its revenue rose 6% year on year to $45,8bn, despite a huge decline from its Covid medicines (it has now withdrawn its Covid vaccine due to low demand).

Excluding these, total revenue actually jumped 15% and product sales increased 14%. And core earnings per share (EPS) advanced 15% to $7.26.

CEO Pascal Soriot said: “We expect another year of strong growth in 2024, driven by continued adoption of our medicines across geographies. Our differentiated and growing portfolio of approved medicines, global reach and rich R&D pipeline give us confidence that we will continue to deliver industry-leading growth.”

Looking ahead, the oncology market is sadly set to grow due to rising cases of cancer globally. But AstraZeneca is a world-leader here. Its blockbuster cancer drug, Tagrisso, has proven to reduce the risk of the disease spreading by an incredible 84% in patients with a type of Stage 3 lung cancer.

Risks to consider

After rising 16% year to date, the stock isn’t exactly cheap at 19.2 times forward earnings. That’s far less than Footsie peer GSK, which is trading at just 10.1 times forecast earnings for 2024.

However, I think this disparity simply reflects the much faster growth of AstraZeneca, its far deeper pipeline of drugs, and GSK’s ongoing litigation issues. A judge in the US has just allowed over 70,000 lawsuits alleging GSK’s discontinued heartburn drug, Zantac, caused cancer.

Of course, that doesn’t mean AstraZeneca couldn’t one day face similar problems. Litigation is a key risk in the pharma industry, as is adverse regulation, patent expirations, and clinical trial failures.

I’d still invest today

Longer term though, I’m very bullish on the sector and AstraZeneca in particular.

This is due to the powerful trend of a rapidly ageing global population, especially in China where the company has a growing presence. This could boost demand for its medicines for decades.

And with the firm aiming to grow revenue by 75% to $80bn by 2030, I think the shares will continue to handily outperform the FTSE 100. That’s why I treated myself to a few not long back.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ben McPoland has positions in AstraZeneca Plc. The Motley Fool UK has recommended AstraZeneca Plc and GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

£10k in an ISA? Here’s how I’d aim to generate a ton of passive income

I dream of escaping the shackles of a salary with financial independence and a steady stream of passive income. Here’s…

Read more »

Investing Articles

Are Burberry shares a bargain or a value trap?

Appearances can be misleading in the stock market. Shares that look like a bargain can turn out to be a…

Read more »

Investing Articles

How I’d target £17,673 passive income with just £100 a week

Our Foolish writer explains how he’d build a portfolio capable of generating a life-changing passive income with limited capital.

Read more »

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing Articles

If I’d put £20k into a FTSE All-Share tracker fund 10 years ago, here’s what I’d have now

A lot of UK investors have money in FTSE All-Share tracker funds. Here, Edward Sheldon looks at how these products…

Read more »

Investing Articles

How I’d invest £10k in a SIPP to target £28,000 annual passive income

Investing just £10k today in a SIPP could be the key to a chunky retirement income in the long run.…

Read more »

Investing Articles

How I could earn a second income worth £35,000

Millions of us invest for a second income. Our writer explains how he's making it work and shares tips for…

Read more »

Investing Articles

3 ways Labour could impact the Rolls-Royce share price

Labour have swept to power on a pro-worker, pro-business ticket. But how could the new government influence the Rolls-Royce share…

Read more »

Fans of Warren Buffett taking his photo
Investing Articles

No savings at 35? I’d use Warren Buffett’s method to try and build massive wealth

Warren Buffett made most of his multi-billion-dollar fortune after turning 50. So what was his trick to building enormous wealth…

Read more »